Pfizer and Valneva: Their Lyme Disease Vaccine Effective Over 70%
Pfizer and Valneva announced on Monday the positive results of the phase 3 VALOR clinical trial of their Lyme disease vaccine candidate. The companies are preparing regulatory submissions following these results.
Effective Prevention in Clinical Trials
The vaccine candidate LB6V, formerly known as VLA15, demonstrated an efficacy rate of over 70% in preventing Lyme disease in individuals aged five years and older in the VALOR trial. The vaccine was well tolerated, and no safety concerns were identified at the time of data analysis.
Regulatory Submissions Planned
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning
✓ Euronext data
✓ AI-powered analysis
Indicative data. No investment advice. Unsubscribe at any time.
Pfizer plans to submit the vaccine candidate to regulatory authorities. These results bolster confidence in the vaccine candidate's profile, according to the press release.
Related
🏢
Other stocks — Santé
🗞️
Sanofi shares lose ground and fall back to their lowest level in a year
🗞️
Abivax stock declines but retains nearly 38% gain over one year
🗞️
Medincell stock plunges 22% in three months and breaks through its support levels
🗞️
MaaT Pharma: Negative CHMP Voting Trend on MaaT013 (Xervyteg)
